Abstract D-Pantethine is a conjugate of the vitamin pantothenic acid and the low-molecular-weight aminothiol cysteamine. Pantethine is an experimental hypolipemic agent and has been suggested as a source of cysteamine in the treatment of nephropathic cystinosis. We treated four cystinotic children with 70-1,000 mg/kg per d oral D-pantethine and studied its metabolism. Pantethine was rapidly hydrolyzed to pantothenic acid and cysteamine; we could not detect pantethine in plasma after oral administration. The responsible enzyme, "pantetheinase," was highly active in homogenates of small intestinal mucosa and plasma. The Michaelis constant of the rat intestinal enzyme was 4.6 MM and its pH profile showed a broad plateau between 4 and 9. Pantothenate pharmacokinetics after orally administered pantethine followed an open two-compartment model with slow vitamin elimination (t1/2 = 28 h). Peak plasma pantothenate occurred at 2.5 h and levels over 250 MM were seen at 300 times normal. Apparent total body storage of pantothenate was significant (25 mg/kg), and plasma levels were elevated threefold for months after pantethine therapy. Plasma cysteamine concentrations after pantethine were similar to those reported after equivalent doses of cysteamine. However, at best only 80% white blood cell cystine depletion occurred. We conclude that pantethine is probably less effective than cysteamine in the treatment of nephropathic cystinosis and should only be considered in cases of cysteamine intolerance. Serum cholesterol was decreased an average of 14%, which supports the potential clinical significance of pantethine as a hypolipemic agent. Rapid in vivo hydrolysis of pantethine suggests that pantothenate or cysteamine may be the effectors of its hypolipemic action.
Introduction
Pantetheine, the amide conjugate of pantothenic acid and cysteamine, occurs naturally as a portion of coenzyme A and the phosphopantetheine of acyl-carrier protein. These coenzymes are extensively involved in carbohydrate, lipid, and amino acid metabolism (1) and use the terminal thiol of pantetheine for transfer of acyl groups.
Pantethine, the disulfide dimer ofpantetheine, has been promoted for clinical use as a hypolipemic agent. It is marketed in Japan (Pantosin; Daiichi Seiyaku Co., Ltd., Tokyo) and Italy (Pantetina; Maggioni Farmaceutici SPA, Milano) as a "natural" hypolipemic drug without side effects. Several clinical trials with dyslipidemic patients have shown decreased total serum cholesterol ( 10-20%) and triglycerides (1 5-68%) , with increased high density lipoprotein, cholesterol and apolipoprotein Al levels (2-1 1). These beneficial effects are assumed to be secondary to increased levels of intracellular pantothenate coenzymes. Animal studies suggest that pantethine is more effectively conserved and used than pantothenic acid (12) . Direct phosphorylation of pantetheine by pantothenate kinase (1) would bypass the first three steps of coenzyme A biosynthesis required when pantothenate is the initial substrate.
A second possible clinical use of pantethine is as a source of cysteamine for the treatment of nephropathic cystinosis (13, 14) . In this autosomal recessive storage disease (15) , cystinotic cells accumulate cystine because of a defective lysosomal membrane transport system ( 16, 17) . Cysteamine can deplete intralysosomal cystine in vitro and in vivo (18) (19) (20) by a disulfide interchange reaction that produces cysteine and cysteamine-cysteine mixed disulfide ( 14) , both ofwhich can freely leave cystinotic lysosomes. Although cysteamine can be given exogenously, it can also be generated endogenously from pantetheine by the enzyme "pantetheinase" (1, (21) (22) (23) ). Pantethine's depletion of cystine from cystinotic fibroblasts ( 13) and renal cells in culture (24) is considered secondary to its production of cysteamine (14) . Pantethine has very low toxicity (25, 26) compared with cysteamine (27) and might serve as a neutral systemic carrier that would target cysteamine intracellularly, avoiding toxicity and maximizing effectiveness. Since the kidney has been considered the principal site ofpantethine degradation to cysteamine (12) , pantethine might be particularly appropriate for treatment of cystinotic children who often develop kidney failure by 10 yr of age.
Both of the above proposed mechanisms for pantethine's action, i.e., accelerated coenzyme A biosynthesis and directed cysteamine transport, require that pantethine reach target cells before hydrolysis to pantothenate and cysteamine. Previous investigations of pantethine metabolism in animals (12, [28] [29] [30] [31] [32] have differed as to the degree ofpantethine hydrolysis that occurs during intestinal absorption. Both predominantly intact absorption (28) and complete hydrolysis (32) have been claimed for the rat. Prior study of pantethine metabolism in humans is limited to a single report (33) on the urinary excretion ofpantethine and pantothenate after intramuscular injection with pantethine.
Although derived from and strictly applicable only to cystinotic subjects, much ofour data may also represent pantethine metabolism in normal humans. At least one aspect of pantethine metabolism, the activity of pantetheinase in fibroblasts and leukocytes, is normal in cystinotics (23). The Patient 3, a 10-yr-old white male, had discontinued cysteamine treatment 6 mo before admission due to liver disease. The particulars of his case have been described (34, 35 (17 samples) exhibited any pantethine by this method; however, prior removal of pantothenate from urine samples by ion exchange allowed a more sensitive assay for urinary pantethine. Over 99% of the pantothenate in 0.5 ml of urine could be removed by passing it through a 0.7 X 2-cm column of Dowex 1 X 4 (OH-form, 100-200 mesh) and washing it with 4.5 ml of water. The eluant was neutralized with phosphate buffer and pantethine was measured as the difference between free and total pantothenate as above. The recovery of pantethine by this method was -80%.
Plasma cysteamine was measured by reaction with radiolabeled cystine thiosulfonate and separation by high voltage electrophoresis (38) . Urinary inorganic sulfate was determined by turbidimetry of barium sulfate, and total sulfur by prior wet oxidation with nitric and perchloric acids in the presence of vanadate as catalyst (39) . Recovery of sulfur from pantethine by this procedure was 96%.
Leukocytes, harvested by dextran sedimentation and hypotonic lysis of red blood cells (40) , were lysed by brief sonication and protein-precipitated in sulfosalicylic acid (final concentration, 3%). Cystine in the supernatant was measured by a competitive binding assay (41) . Protein was measured with Folin's phenol reagent (42) with bovine serum albumin as standard.
Supernatants of random stool samples were analyzed for osmolality and electrolytes by the hospital laboratory, and for total sulfur, cysteamine, pantothenate, and pantethine by the methods described above.
Excess small bowel biopsy material from a 10-yr-old boy (kindly supplied by Dr. William Byrne, University of Michigan, MI) with malabsorption was obtained, which was later histologically identified as normal. The sample was immediately homogenized in 4 vol of cold 0.02 M Tris-HCI, pH 8.2. Pantetheinase activity was measured by the pantothenate assay (43) , modified as follows: 40 ,ug of mucosal protein was incubated with 1 meq ofdithiothreitol and 1, 2, or 1 I meq of pantethine in 0.05 M Tris-HCl, pH 8.2, for 80 min at 37°C in a total volume of 100 s1.
Male Sprague-Dawley rats were killed by decapitation and small intestinal mucosa were scraped off with a glass rod. The mucosal samples were homogenized in 4 vol of cold 0.02 M Tris-HCl, pH 8.2. 25 Ml of the homogenate was prereduced and enzyme activity was determined according to the pantothenate assay (43) . Glycine-HCl, acetate, phosphate, Tris-HCl, and carbonate buffers were used at 0.25 M final concentration to measure activity between pH 2 and 10. Double reciprocal plots of kinetic data were used for Michaelis constant (K.) determination.
Statistical analysis employed the t test on the paired percentage difference of values. Since analysis ofthe first 13 pairs of 1-and 5-h postdose plasma samples revealed no significant difference between paired values in terms ofpantothenate (P > 0.05), cysteamine (P > 0.3), and leukocyte cystine (P > 0.2) concentrations, the 1-and 5-h values were averaged.
Results
Intestinal pantetheinase. Pantetheine-degrading activity was detected in both rat and human intestine. The pH profile for rat intestinal pantetheinase showed a broad plateau between pH 4 and 9, and the enzyme followed Michaelis-Menten kinetics with a Km of4.6 ,M (data not shown). Human small intestinal mucosa had a pantetheinase specific activity of 1.2 nmol/min per mg protein and showed inhibition by excess pantethine. When the ratio of pantethine to pantetheine (pantethine reduced by dithiothreitol) in the reaction mixture was increased from 0 to 1 to 10, enzymatic activity decreased from 100 to 79 to 70%, respectively. Known properties of pantetheinase from different tissues are given in (Fig. 3) .
Pantothenate excretion was also highly dependent on the cumulative dose of pantethine (Fig. 4) . The proximately half the creatinine clearance (Fig. 5) . However, between 20 and 60 AM pantothenate, the fractional excretion of pantothenate was well above 1, while above 60 MAM, pantothenate clearance decreased to that of creatinine. Cysteamine and cystine metabolism. Plasma cysteamine concentration increased with pantethine dose in a similar manner for three of the four subjects (Fig. 6) . When organic sulfur excretion (the difference between total sulfur and inorganic sulfate excretion) was plotted against pantethine dose, a similar rapid rise, followed by a plateau, was seen (data not shown). Inorganic sulfate excretion varied in a biphasic manner with pantethine dose (Fig. 7) . Plasma Pantothenate (pm) Figure 5 . Dependence of the fractional excretion of pantothenate on the concentration of plasma pantothenate. Protocols of pantethine treatment were the same as in Fig. 3 Figure 6 . Plasma cysteamine dependence on pantethine dose. Protocols of pantethine treatment were the same as in Fig. 3 . Plasma samples obtained 1 and 5 h after the last dose at a particular level were analyzed for cysteamine (38) and averaged. Patient symbols are the same as in Fig. 3 . Fig. 8 shows the time variation of plasma pantothenate, plasma cysteamine, and leukocyte cystine depletion on different doses and dosage schedules of oral pantethine. Plasma pantothenate remained nearly constant for 6 h and plasma cysteamine for 4 h after a dose. Administering 250 mg/kg per d pantethine three times a day with meals, as opposed to every 6 h, doubled plasma pantothenate, increased plasma cysteamine, and increased leukocyte cystine depletion. Increasing the dose to 1,000 mg/kg per d did not alter plasma cysteamine and appeared to decrease leukocyte cystine depletion.
Leukocyte cystine depletion correlated poorly with pantethine dose (Fig. 9 A) but reasonably well with plasma cysteamine (Fig. 9 B) . The maximum leukocyte cystine depletion achieved was 80%.
Clinical side effects. No serious side effects were seen with pantethine treatment. Base-line laboratory tests, including liver function tests, were not changed appreciably, except that fasting serum cholesterol (initial range, 212-253 mg/dl) decreased an average of 14.3% (final range, 189-2 10 mg/dl). One patient preferred pantethine's bitter taste to cysteamine, and another found the two drugs "different, but both just as bad." Pantethine Dose (mwq/kg/dnY) Figure 7 . The effect of pantethine dose on inorganic sulfate excretion. Protocols of pantethine treatment were the same as in Fig. 3 . Urine was collected during the last 24 h of treatment at a particular dose and inorganic sulfate was determined by turbidimetry of barium sulfate (39) . Patient symbols are the same as in Fig. 3 . The arrow tails were sampled at 1 h after a dose, while the arrow heads were sampled 6 h after a dose.
Discussion
After high doses of oral pantethine, plasma pantothenate levels were elevated to 300 times normal, and plasma cysteamine levels were comparable to those found after oral cysteamine therapy (45) . However, no pantethine (or pantetheine) could be detected in plasma, which indicated levels <5-10% of the plasma pantothenate concentration. Although the extent to which pantethine is hydrolyzed at the intestinal wall is uncertain, recent animal experiments favor nearly complete hydrolysis (32) . Intestinal pantetheinase has the lowest Km ofthis enzyme for any measured tissue (Table I) . Any panteth(e)ine surviving passage through the intestinal wall would next contact plasma pantetheinase. Assuming substrate saturation, this enzyme circulated at levels sufficient to produce the highest plasma pantothenate concentration observed in this study in <30 min. We conclude that pantethine is hydrolyzed before distribution to tissues and cannot be used to target cysteamine intracellularly for an increased therapeutic ratio in the treatment of nephropathic cystinosis. However, since a small fraction (<1%) of pantothenate is excreted as pantethine, some pantethine may circulate transiently. This fraction could account for the hypolipemic effect of pantethine. In perfused rat liver, pantethine is a more effective precursor ofcoenzyme A than pantothenate (46). Alternatively, either pantothenate or cysteamine could be responsible for pantethine's hypolipemic action. Cysteamine has numerous pharmacologic actions (21) and hormonal effects (47, 48) . Pantothenate deficiency has been reported to lower blood cholesterol levels in the rat (49) and dog (50) , but this was not demonstrated in humans (51) . We know ofno reports investigating hypolipemic properties of cysteamine or pantothenate.
We have confirmed that pantethine is nontoxic and may be more palatable than cysteamine in some patients with nephropathic cystinosis. No serious side effects were encountered, even though doses up to 70 times those currently employed for hyperlipemia were used (2-1 1). In particular, no elevation of liver function tests occurred (52) . An osmotic diarrhea did occur at doses above 350 mg/kg per d. Absorption was severely limited at high doses, and pantethine, pantothenate, and cysteamine were the major osmotic agents. Most of the pantethine was neither absorbed nor hydrolyzed when given at a dose of 1,000 mg/ kg per d.
The exact cause of the poor absorption is uncertain. Most likely, the absorptive capacity of the intestine is overwhelmed by pharmacologic doses ofan agent usually present only in trace quantities. Delaying the transit time by giving the drug with meals did increase absorption (Fig. 8) . The acidic stool pH (5.5-6.0) could be a contributing factor to poor absorption. The hydrolysis of pantetheine does produce some acid at neutral pH (43) . However, the stool osmolality was also elevated (335 mosM), and both these changes may simply represent continued bacterial metabolism outside of the body. Like pantetheinase from other tissues (1, 21-23) , intestinal pantetheinase requires a reducing environment for full activity. When human intestinal mucosa was incubated with increasing amounts of oxidized pantethine, inhibition of pantetheinase occurred. Perhaps excess pantethine overloads the capacity ofthe intestine for pantethine reduction to pantetheine (53) . The oxidizing intraluminal milieu would inhibit pantetheinase, hydrolysis and absorption would decrease, and an osmotic diarrhea would occur. Our data suggest significant total body storage of pantothenate. Pharmacokinetic studies of pantothenate (Figs. 1 and  2 ) reveal rapid absorption and distribution, with slow excretion (t112 = 28 h). Limited excretion after pantothenate loading has been previously reported (12, 33, 54) . Fig. I indicates 24-h excretion of only 2.5% after a single dose. Fig. 4 is most readily interpreted by assuming a constant pantothenate absorption of 8% with a sigmoid increase in excretion that indicates a gradual saturation of pantothenate stores. Initially, most ofthe absorbed pantothenate would be stored and not excreted. Only with total body saturation would the amount excreted approach the amount absorbed. If the abscissa of Fig. 4 is expressed in terms of the cumulative pantethine dose, the area above each curve (but below 8% excretion) can be used to quantitate pantothenate storage. Integration of the difference between absorption and excretion gives a value of -25 mg pantothenate/kg body wt. The amount of pantothenate carried by the plasma is a small fraction of total body storage, and our estimate of pantothenate storage should be valid despite variations in renal function and its possible effect on plasma pantothenate concentration. Indeed, similar values were obtained for both patients in Fig. 4 , even though they had widely different creatinine clearances (67 and 19 ml/min per 1.73 m2).
The fact that plasma pantothenate correlates best with cumulative pantethine dose (Fig. 3 ) also supports significant pantothenate storage. It appears that plasma pantothenate concentration is determined more by chronic total pantothenate load than by current dosage. Absorption and distribution ofany given dose are rapid, but excretion of total body stores is slow. Our samples were measured 1 and 5 h after a dose, away from the peak levels expected at 2.5 h (Figs. 1 and 2 ). Plasma pantothenate was elevated to three times initial values months after pantethine treatment, which indicates continued replacement of pantothenate in the plasma compartment with tissue stores. Storage of pantothenate has previously been suspected (55, 56) . The significance of these findings in terms of functional pantothenate status and coenzyme activity are unknown.
The segregation of subjects onto one of two curves in Fig. 3 is curious. The different responses could indicate initial differences in pantothenate stores. Patients 3 and 4 had higher initial plasma pantothenate levels than patients 1 and 2, and patient 4 had chronically received 10 mg calcium pantothenate/d as a vitamin supplement before the study. An alternative explanation is that both patients 3 and 4 had significant renal insufficiency (both with a creatinine clearance of <20 ml/min per 1.72 M2), and pantothenate was retained in the plasma compartment secondary to a decreased filtration.
The tubular secretion and reabsorption of pantothenic acid in rat kidney have recently been studied (57) . Net reabsorption occurred when plasma pantothenate was below 15 ,gM and net secretion occurred above 15 ASM. The secretory process was saturable and inhibited by penicillin. Fig. 5 reveals a similar renal handling ofpantothenate in cystinotic subjects. At extreme pantothenate concentrations, pantothenate clearance approaches creatinine clearance, which indicates saturation of the secretory mechanism. Since the fractional excretion of pantothenate is plotted in Fig. 5 , variation in renal function is nullified, and extrapolation to normal humans should be justified.
Plasma cysteamine concentrations plateau with increasing pantethine dose (Fig. 6) , which indicates limited intestinal hydrolysis of pantethine (and hence limited production of cysteamine) at higher doses. The osmotic diarrhea at higher pantethine loads begins to occur just where the curve significantly levels off. The aberrant subject (patient 3) had not been treated with cysteamine for the past 6 mo, which perhaps indicates that cysteamine metabolism is induced only after chronic intake. Alternatively, his liver disease (34, 35) may have impaired cysteamine metabolism.
Orally administered cysteamine is excreted as organic sulfur; significant metabolism to inorganic sulfate does not occur (18) . Plots of organic sulfur excretion against pantethine dose were highly variable, perhaps due to dietary intake that was not stringently controlled (data not shown). Nevertheless, a trend to plateau in much the same way as plasma cysteamine was present, which supports limited absorption ofcysteamine at higher doses of pantethine.
In contrast to cysteamine, the major end products ofcystine in humans are inorganic sulfate and taurine (15) . Taurine excretion in cystinotic patients treated with cysteamine is low in comparison with inorganic sulfate excretion (18) . Therefore, inorganic sulfate excretion should follow cystine degradation and reflect total body cystine labilization. Indeed, inorganic sulfate excretion did increase with pantethine treatment (Fig. 7) , perhaps as a result of cystine depletion and degradation. Increasing the dosage of pantethine beyond a certain point did not further increase inorganic sulfate excretion, which reflects limited cysteamine absorption. There was much variability between patients, both in base-line inorganic sulfate excretion and in the rise seen with pantethine treatment. Base-line variance may be due to differences in dietary intake. The variable increase with pantethine treatment seems to correlate with the initial leukocyte cystine level. The higher the initial cystine load (as reflected by pretreatment leukocyte cystine), the greater the labilization of cystine with pantethine treatment (as reflected by increased inorganic sulfur excretion). The possibility of using inorganic sulfate excretion to test the efficacy of alternative cystine-depleting drugs in cystinosis should not be overlooked.
Pantethine absorption was apparently increased by administering the drug three times a day with meals instead of every 6 h (Fig. 8) . Food may increase or decrease drug bioavailability (58) ; increased absorption ofpantethine may have resulted from increased transit time and prolonged exposure to intestinal pantetheinase. Pantethine doses higher than 250 mg/kg per d did little to increase plasma levels of pantothenate and cysteamine (Fig. 8) . The decreased leukocyte cystine depletion at 1,000 mg/ kg per d as compared with 500 mg/kg per d may be related to the marked diarrhea observed at the higher dose. We did not control for potential sequence effects and day-to-day variation in Fig. 8 . Although we do not expect serious artifacts, interpretation should be cautious.
Leukocyte cystine depletion is the conventional indicator of drug effectiveness in the treatment ofcystinosis. Cysteamine can deplete >90% of leukocyte cystine (18, 20) , and therapy is aimed at reducing leukocyte cystine levels to those of clinically unaffected heterozygotes ( 15) . Treatment with pantethine did reduce leukocyte cystine (Fig. 9 A) , but the results were variable and in no case was >80% depletion achieved. Differences in absorption probably explain the poor correlation of leukocyte cystine depletion with pantethine dose. Better correlation was obtained by plotting leukocyte cystine depletion against plasma cysteamine (Fig. 9 B) .
Plasma cysteamine concentrations were similar after equivalent doses of pantethine or cysteamine (Fig. 6 and reference  44) . However, at equal plasma cysteamine concentrations, oral cysteamine was more effective than pantethine at depleting leukocytes of cystine (Fig. 9 B) . The explanation is not entirely clear, but we suspect oral cysteamine results in higher peak plasma levels. The production of cysteamine from pantethine was limited by the rate of enzymatic hydrolysis. A brief but extreme peak exposure to cysteamine may be more effective at initiating the disulfide exchange required for leukocyte cystine depletion than the relatively constant infusion of cysteamine produced by intestinal pantethine hydrolysis.
Since oral pantethine cannot produce the leukocyte cystine depletion that cysteamine can, we do not recommend its use in nephropathic cystinosis and have discontinued clinical trials. However, it might still be useful in cases of cysteamine intolerance. Another option, currently being investigated, is the use of phosphocysteamine (59) .
